Do these neural-target antibodies span myelin, neuronal structure, neurotransmitter signaling, and synaptic proteins?

The claim is substantially supported: these reported reactivities span several neural biological domains, but antibody detection alone cannot establish pathogenicity or active neural injury. The important qualification is that direct serotonin-antibody specificity has not been verified.

Target biology and mechanistic context

• Myelin basic protein is a myelin constituent; tubulin is a cytoskeletal/neuronal-structural protein; dopamine D2 receptor (D2R) is a cell-surface GPCR involved in dopaminergic signaling; and amphiphysin is an intracellular presynaptic protein required for clathrin-mediated synaptic-vesicle endocytosis.
• D2R has the most direct signaling-related support: patient IgG binding has been demonstrated with cell-surface assays, extracellular-peptide blocking, and receptor-signaling experiments.
• Amphiphysin IgG can disrupt synaptic-vesicle recycling in neuronal models. However, because amphiphysin is intracellular, associated disease often reflects cytotoxic T-cell-mediated paraneoplastic immunity rather than antibody-mediated injury alone.
• Serotonin is a neurotransmitter, but available findings support only possible serotonin-receptor cross-reactivity—not confirmed antibodies directed against serotonin itself.

Clinical interpretation and safety implications

• A positive result does not diagnose autoimmune neurological disease or show that antibodies are causing current neuronal damage. Interpretation requires a compatible, usually subacute phenotype plus objective support: paired serum/CSF testing, CSF inflammation, MRI, EEG, seizures or focal deficits, and exclusion of infectious, vascular, neurodegenerative, metabolic, medication-related, and malignant alternatives.
• Assay type matters: MBP and tubulin assays using purified antigen may detect denatured or linear epitopes rather than clinically meaningful native-target binding. Low-level or serum-only positivity is especially insufficient for causal inference.
• Confirmed amphiphysin IgG is strongly associated with paraneoplastic neurologic syndromes, including stiff-person syndrome or encephalomyelitis, and should prompt tumor evaluation—but remains an association, not proof of direct ongoing antibody injury.

Bottom line

• These antibodies may identify biologically relevant targets, but their presence alone neither proves pathogenicity nor establishes active neural injury; clinical syndrome, validated testing, compartmental evidence, and objective inflammatory/injury findings are decisive.